Abstract:The nucleotide-binding, oligomerization domain-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a multiprotein complex that combines sensing, regulation, and effector functions to regulate inflammation in health and disease. NLRP3 is activated by a diverse range of inflammation-instigating signals known as pathogen associated molecular patterns and danger associated molecular patterns. Upon activation, NLRP3 oligomerizes and recruits partner proteins to form a supramolecular platform to process the maturation and release of interleukin (IL)-1 β , IL-18, and gasdermin D, major mediators of inflammation and inflammatory cell death termed pyroptosis. The NLRP3 inflammasome has been implicated in the pathogenesis of a wide range of disease conditions, including chronic inflammatory disease that are associated with lifestyle and dietary changes, aging, and environmental exposures, and have become the leading cause of death worldwide. Pharmacological targeting of NLRP3 and signaling demonstrated promising efficacy in ameliorating a list of disease conditions in animal models. These findings underscore the potential and importance of NLRP3 as a druggable target for treating a range of diseases. In this review, recent progress in understanding the structure and mechanism of action of the NLRP3 inflammasome is discussed with focus on pharmacological inhibition of NLRP3 by small molecule inhibitors. New structural and mechanistic insights into NLRP3 activation and inhibitor-NLRP3 interactions would aid in the rational design and pharmacological evaluation of NLRP3 inhibitors for treatment of human disease. Significance Statement The NLRP3 inflammasome plays central role in innate immune sensing and control of inflammation. Pharmacological inhibition of NLRP3 demonstrated promising efficacy in a range of diseases in animal models. Recent elucidation of the structure and inhibitor binding of NLRP3 generated new insights into its mode of action and inhibitor-NLRP3 interaction at molecular levels, providing new framework for developing small chemical inhibitors of NLRP3 with improved efficacy and specificity against chronic disease that has become major health concerns worldwide.

Multiple sclerosis: the NLRP3 inflammasome, gasdermin D, and therapeutics

Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis

Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics

The NLRP3 inflammasome: molecular activation and regulation to therapeutics

Investigating the NLRP3 Inflammasome and its Regulator miR‐223‐3p in Multiple Sclerosis and Experimental Demyelination

Recent Insights into the Regulatory Networks of NLRP3 Inflammasome Activation

NLRP3 inflammasome and its inhibitors: a review

The NLRP3 inflammasome: contributions to inflammation-related diseases

Role of the NLRP3 inflammasome in autoimmune diseases

NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies

The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors

Advanced Researches on the Regulation of NOD-like Receptor Pyrin Domain Containing 3 Inflammasomes

NLRP1 inflammasome in neurodegenerative disorders: From pathology to therapies

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

The NLRP3 inflammasome: activation and regulation

Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis

Regulation of the NLRP3 inflammasome by autophagy and mitophagy

The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

Pharmacological Inhibitors of the NLRP3 Inflammasome